Scholarlink

Background <p>Chronic rhinosinusitis (CRS) is a common inflammatory disorder associated with persistent sinonasal symptoms and impaired quality of life. Despite available conventional therapies, many patients experience incomplete relief or adverse effects, highlighting the need for safe and sustainable alternative approaches.</p> Objective <p>To evaluate Clinical and Radiological Outcomes of Itrifal Ustukhudus (<i>Itrifal Ustukhudus</i>,<i> a classical Unani polyherbal formulation containing Lavandula stoechas along with Triphala components (Terminalia chebula</i>,<i> Terminalia bellerica</i>,<i> and Phyllanthus emblica</i>)) in Chronic Rhinosinusitis in a prospective real-world surveillance.</p> Methods <p>This prospective, open-label, single-arm surveillance study included 100 adults with chronic rhinosinusitis (CRS) (37 males, 63 females). Participants received Itrifal Ustukhudus for six weeks and were assessed at 15-day intervals during the treatment period. Clinical outcomes were evaluated using the Sino-Nasal Outcome Test-22 (SNOT-22), while radiological changes were assessed using standardized imaging criteria. Safety evaluation included haematological parameters, liver and kidney function tests, erythrocyte sedimentation rate (ESR), and serum uric acid levels. Longitudinal changes were analysed using linear mixed-effects models for repeated measures, with statistical significance set at <i>p</i> &lt; 0.05.</p> Results <p>Participants demonstrated substantial reductions in SNOT-22 scores from baseline to the end of treatment, indicating marked improvement in sinonasal symptom burden. Radiological improvement was observed in more than half of the participants, with the most notable changes seen in individuals with bilateral sinus involvement. Laboratory parameters, including haematological indices and liver and kidney function markers, remained stable throughout the study period, suggesting an acceptable safety profile. Reductions in ESR and serum uric acid levels were also observed, indicating a potential reduction in systemic inflammatory activity.</p> Conclusion <p>Itrifal Ustukhudus was associated with clinically meaningful improvements in symptoms and favourable radiological trends, with a reassuring safety profile during the study period. However, given the open-label, single-arm design, these findings should be interpreted as preliminary and hypothesis-generating.</p> CTRI no <p>CTRI/2018/10/016178.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multidimensional analysis and clinical efficacy: evaluating the therapeutic and metabolic potential of Itrifal Ustukhudus in chronic rhinosinusitis management with four-month surveillance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月2日

查看全文
  • Huma Rafiq,
  • Arif Habib,
  • Shaista Urooj,
  • Arjumand Shah,
  • Kounser Shah,
  • Arsheed Iqbal,
  • Sabia Rasool

摘要

Background

Chronic rhinosinusitis (CRS) is a common inflammatory disorder associated with persistent sinonasal symptoms and impaired quality of life. Despite available conventional therapies, many patients experience incomplete relief or adverse effects, highlighting the need for safe and sustainable alternative approaches.

Objective

To evaluate Clinical and Radiological Outcomes of Itrifal Ustukhudus (Itrifal Ustukhudus, a classical Unani polyherbal formulation containing Lavandula stoechas along with Triphala components (Terminalia chebula, Terminalia bellerica, and Phyllanthus emblica)) in Chronic Rhinosinusitis in a prospective real-world surveillance.

Methods

This prospective, open-label, single-arm surveillance study included 100 adults with chronic rhinosinusitis (CRS) (37 males, 63 females). Participants received Itrifal Ustukhudus for six weeks and were assessed at 15-day intervals during the treatment period. Clinical outcomes were evaluated using the Sino-Nasal Outcome Test-22 (SNOT-22), while radiological changes were assessed using standardized imaging criteria. Safety evaluation included haematological parameters, liver and kidney function tests, erythrocyte sedimentation rate (ESR), and serum uric acid levels. Longitudinal changes were analysed using linear mixed-effects models for repeated measures, with statistical significance set at p < 0.05.

Results

Participants demonstrated substantial reductions in SNOT-22 scores from baseline to the end of treatment, indicating marked improvement in sinonasal symptom burden. Radiological improvement was observed in more than half of the participants, with the most notable changes seen in individuals with bilateral sinus involvement. Laboratory parameters, including haematological indices and liver and kidney function markers, remained stable throughout the study period, suggesting an acceptable safety profile. Reductions in ESR and serum uric acid levels were also observed, indicating a potential reduction in systemic inflammatory activity.

Conclusion

Itrifal Ustukhudus was associated with clinically meaningful improvements in symptoms and favourable radiological trends, with a reassuring safety profile during the study period. However, given the open-label, single-arm design, these findings should be interpreted as preliminary and hypothesis-generating.

CTRI no

CTRI/2018/10/016178.